Start-up to develop radiotherapeutics | Chemical & Engineering News
Volume 95 Issue 10 | p. 15 | Concentrates
Issue Date: March 6, 2017

Start-up to develop radiotherapeutics

Department: Business
Keywords: oncology, radiotherapeutics, drug discovery

Fusion Pharmaceuticals has launched to develop α-particle radiotherapeutics for treating cancer. The new firm, based in Hamilton, Ontario, received $25 million in series A financing from Johnson & Johnson and other investors. Fusion was founded by John Valliant, a chemist who also founded the Centre for Probe Development & Commercialization at Canada’s McMaster University. Fusion’s lead product, FPX-01, will deliver actinium-225 to tumor cells with the help of a centyrin-based targeting molecule from J&J’s Janssen Biotech unit.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment